BOT is about to release results (soon) on their psoriasis drug.
They're testing this on a larger cohort of patients, hence the phase 1b trial.
However, it's important to note that theyve already seen positive results for this drug in a patient. Not an animal, not a stem cell derived model. A human.
Expanding this to a larger cohort should see similar (positive) results due to the genetics of the condition. Genetic variability is lesser, and derma conditions of the more superficial layers are easier to treat without being prone to changes due to pigmentation deposits and other genetic factors albeit environmental factors.
Like any bio company, there is a chance this won't be as good as I think. However, assuming they're controlling their patient samples (they would be) I'd take a stab to guess that we may be in for a nice month.
Also someone linked the trial outline a while back (can't find it but it's on the national registry). It's in all states and includes large patient groups with a very comprehensive outline. You don't spend that sort of money taking a drug to trial if you didn't think it'll have good results; you rule that out in-vitro models. That's the point.
Lest we forget we have 3 products. A new director. A some rapport overseas and from dermatologists already - that's nice.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)